11. CONFLICT OF INTEREST
All members of the NMIBC and UTUC Guidelines working group have provided disclosure statements on all relationships that they have that might be perceived to be a potential source of a conflict of interest. This information is provided below and is also publicly available on the EAU website: https://uroweb.org/guidelines/upper-urinary-tract-urothelial-cell-carcinoma/panel.
This Guidelines document was developed with the financial support of the EAU. No external sources of funding and support have been involved. The EAU is a non-profit organisation, and funding is limited to administrative, travel and meeting expenses. No honoraria or other reimbursements have been provided.
Disclosures: The EAU Guidelines Office certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/ affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following:
A. Masson-Lecomte (Chair) reported receiving company speaker honoraria fees from Astellas Pharma, BMS, Ferring, Medac and MSD; attending advisory board meetings as a company consultant to Janssen Global Bladder Cancer and Pfizer; being an academy faculty advisor to Photocure; receiving grants or research support from Ferring and Ipsen Pharma; and participation in clinical trials by Janssen Cilag and MSD. J. Baard reported receiving company honoraria or consultation fees from Astellas, Boston Scientific, Coloplast, Cook, GSK, Olympus, Storz, TSC life and UroGen Pharma; and receiving fellowship or travel grant support from Astellas. A. Birtle reported receiving company speaker honoraria fees from Johnson & Johnson, Astellas, MSD, Merck, Accord and Bayer; serving as a company consultant to MSD, Bayer, Macrogenics and Ipsen; serving on the advisory board of Macrogenics, Johnson & Johnson, Astellas, Merck and AstraZeneca; being a trustee/medical advisor to Fight Bladder Cancer; and being a member of the ESMO Educational Committee. E.M. Compérat reported serving as a company consultant to Daiitchi, Johnson & Johnson and Astra. J.L. Dominguez-Escrig reported receiving company speaker honoraria fees from Presurgy, BMS and Angiodynamics; attending advisory board meetings as a company consultant to Astellas; and participation in clinical trials by Janssen, Arquer, Physion, Combat BRS, Ipsen, Storz, Uromonitor, Fidia Farmaceutici and Angiodynamics. P. Gontero reported receiving company speaker honoraria fees from Merck, Janssen and Medac; serving as a company consultant to Ferring, Medac, Pfizer, Photocure, MSD and AstraZeneca; receiving grants or research support from Intuitive Surgical, Astellas and Ferring; acting as chair of the institution for clinical trials by Johnson & Johnson; and participation in clinical trials by Ferring and Catalym. P. Mariappan reported receiving company speaker honoraria fees from BMS, Janssen Cilag, Medac Pharma and Photocure; serving on the core committee of the International Bladder Cancer Group; receiving grants or research support from Nucleix; and participation in clinical trials by Nucleix. B. Pradere reported receiving company honoraria or consultation fees from Astellas Pharma, Ferring, Johnson & Johnson, Laboratoires MSD, Ipsen Pharma and Photocure; serving as a company consultant to Johnson & Johnson; and participation in clinical trials by AstraZeneca and Johnson & Johnson. B.P. Rai reported receiving company speaker honoraria fees from Ipsen, Janssen-Cilag and Bayer. B.W.G. van Rhijn reported receiving advisory board meeting company consultation fees from Cepheid. T. Seisen reported receiving company honoraria or consultation fees from ADACAP, Astellas, Bayer, BMS, Ipsen, Janssen, MSD, Pfizer and VitaDX; receiving grants or research support from Institut de Recherche Servier and Ipsen; receiving fellowship or travel grant support from Institut de Recherche Servier; and participation in clinical trials by AstraZeneca, Ferring, Janssen and Roche. S.F. Shariat reported receiving company honoraria or consultation fees from Astellas Pharma, AstraZeneca, Bayer Austria, BMS, Ferring, Johnson & Johnson, MSD and Pfizer; and is the owner of four patents. J. Teoh reported receiving company speaker honoraria fees from Ferring Pharmaceuticals, Olympus Corporation and Astellas; serving as a company consultant to Johnson & Johnson, Ferring and MSD; receiving grants or research support from Olympus Corporation; and participation in clinical trials by AstraZeneca, BMS and Johnson & Johnson. E.N. Xylinas reported receiving company honoraria or consultation fees from Pfizer, Astellas, AstraZeneca, Boston Scientific, BMS, Ferring, Johnson & Johnson, Merck, MSD and Pfizer; receiving grants or research support from AstraZeneca, Boston Scientific and Ferring; participation in clinical trials by AstraZeneca, Janssen Cilag, MSD and Pfizer; and serving in a leadership role for the Association Française d’Urologie. D. D’Andrea reported receiving company speaker honoraria fees from Merck, Photocure, Olympus and Pfizer; and serving as a company consultant to Cepheid. O. Capoun reported receiving company honoraria or consultation fees from Accord Healthcare, Astellas Pharma, AstraZeneca, Bayer, Janssen and Novartis; and participation in clinical trials by Bayer and Janssen. M. Moschini reported receiving company honoraria or consultation fees from Janssen Cilag, Medac Pharma, Photocure and Johnson & Johnson; and serving as a company consultant to Pfizer Italiana. F. Soria reported receiving company honoraria or consultation fees from Medac Pharma, Johnson & Johnson, Photocure, Pfizer, AstraZeneca and Cepheid; and participation in clinical trials by Fidia Farmaceutici, Janssen, Steba biotech and Catalym. F. Liedberg, V. Soukup, E. Fiorini and R. Wood have nothing to declare.